Supernus Pharma (SUPN) Misses Q1 EPS by 13c, Revenues Beat; Offers FY21 Revenues Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Supernus Announces First Quarter 2021 Financial Results
May 5, 2021 4:01 PM EDTFirst quarter 2021 total revenues of $130.9 million, a 38% increase compared to 2020Qelbree approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2 2021Qelbree sNDA submission for adult ADHD anticipated in the third quarter of 2021SPN-830 (apomorphine infusion pump) NDA resubmission anticipated in the second half of 2021SPN-820 (mTORC1) has advanced towards a Phase II clinical program in treatment-resistant depression following successful completion of MAD study
ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Supernus... More
